Characteristics of patients 16 years of age or older who underwent URD SCT for Philadelphia-negative ALL in CR1, reported to the CIBMTR between 1995 and 2004
| Characteristics of patients . | No. evaluable . | N (%) . |
|---|---|---|
| No. of patients | 169 | |
| No. of centers | 85 | |
| Age, median, y (range) | 169 | 33 (16-59) |
| Age at transplantation, y | 169 | |
| 20 or younger | 37 (22) | |
| 21 to 30 | 35 (21) | |
| 31 to 40 | 49 (29) | |
| 41 to 50 | 29 (17) | |
| 51 to 60 | 19 (11) | |
| Male sex | 169 | 101 (60) |
| Karnofsky score prior to transplantation less than 90% | 161 | 41 (25) |
| Lineage | 169 | |
| T | 169 | 32 (19) |
| B | 99 (58) | |
| Unknown | 38 (23) | |
| FAB subtype | 169 | |
| ALL, NOS | 8 (5) | |
| ALL T-cell | 32 (19) | |
| ALL null cell (early Pre-B) | 14 (8) | |
| ALL cALLa (including Pre-B) | 58 (34) | |
| ALL, B-lineage, NOS | 27 (16) | |
| ALL other | 30 (18) | |
| WBC at diagnosis, ×109/L | 155 | 31 (<1-776) |
| Less than 30 | 77 (50) | |
| 30 to 100 | 40 (26) | |
| 100 to 200 | 25 (16) | |
| More than 200 | 13 (8) | |
| Site of extramedullary disease | 169 | |
| CNS with or without another | 21 (12) | |
| Other* | 10 (6) | |
| No extramedullary disease | 138 (82) | |
| Time from diagnosis to CR1 | 168 | |
| Less than 4 wk | 43 (26) | |
| 4 to 8 wk | 55 (33) | |
| More than 8 wk | 70 (42) | |
| Time from CR1 to transplantation | 169 | |
| Less than 3 mo | 58 (34) | |
| 3 to 6 mo | 70 (41) | |
| More than 6 mo | 41 (24) | |
| Time from diagnosis to transplantation | 169 | |
| Less than 3 mo | 4 (2) | |
| 3 to 6 mo | 67 (40) | |
| More than 6 mo | 98 (58) | |
| Cytogenetics | 169 | |
| t(4;11) with or without others | 27 (16) | |
| Hypodiploid (no t(4;11) or t(8,14)) with or without others | 10 (6) | |
| Five or more abnormalities | 5 (3) | |
| Other | 60 (35) | |
| No abnormalities | 67 (40) | |
| Conditioning regimen | ||
| Cy plus TBI with or without another | 129 (76) | |
| TBI with or without another (no Cy) | 25 (15) | |
| Cy with or without another (no TBI) | 11 (7) | |
| Other | 4 (2) | |
| TBI dose, cGy | 153 | 1200 (200-1500) |
| Less than 1300 | 31 (21) | |
| More than 1300 | 121 (79) | |
| Cyclophosphamide dose, mg/kg | 140 | 117 (8-200) |
| Less than 100 | 32 (23) | |
| 100 to 120 | 55 (39) | |
| More than 120 | 53 (38) | |
| Donor age, y | 163 | 33 (19-56) |
| 20 or younger | 2 (1) | |
| 21 to 30 | 62 (38) | |
| 31 to 40 | 66 (40) | |
| 41 to 50 | 31 (19) | |
| 51 to 60 | 2 (1) | |
| Donor-recipient sex match | 168 | |
| M-M | 75 (44) | |
| M-F | 32 (19) | |
| F-M | 25 (15) | |
| F-F | 36 (21) | |
| Donor-recipient CMV status | 166 | |
| +/+ | 41 (25) | |
| +/− | 28 (17) | |
| −/+ | 44 (27) | |
| −/− | 53 (31) | |
| Donor-recipient HLA match† | 169 | |
| Well matched | 70 (41) | |
| Partially matched | 70 (41) | |
| Mismatched | 29 (18) | |
| Graft type | 169 | |
| Bone marrow | 117 (69) | |
| Peripheral blood | 52 (31) | |
| Year of transplantation | 169 | |
| 1995 to 1996 | 27 (16) | |
| 1997 to 1998 | 23 (14) | |
| 1999 to 2000 | 27 (16) | |
| 2001 to 2002 | 36 (21) | |
| 2003 to 2004 | 56 (33) | |
| GVHD prophylaxis | 169 | |
| (FK506 or CsA) plus MTX with or without another | 130 (77) | |
| T-cell depletion‡ | 16 (9) | |
| Other§ | 23 (14) | |
| Median (range) follow-up of survivors, mo | 54 (3-133) |
| Characteristics of patients . | No. evaluable . | N (%) . |
|---|---|---|
| No. of patients | 169 | |
| No. of centers | 85 | |
| Age, median, y (range) | 169 | 33 (16-59) |
| Age at transplantation, y | 169 | |
| 20 or younger | 37 (22) | |
| 21 to 30 | 35 (21) | |
| 31 to 40 | 49 (29) | |
| 41 to 50 | 29 (17) | |
| 51 to 60 | 19 (11) | |
| Male sex | 169 | 101 (60) |
| Karnofsky score prior to transplantation less than 90% | 161 | 41 (25) |
| Lineage | 169 | |
| T | 169 | 32 (19) |
| B | 99 (58) | |
| Unknown | 38 (23) | |
| FAB subtype | 169 | |
| ALL, NOS | 8 (5) | |
| ALL T-cell | 32 (19) | |
| ALL null cell (early Pre-B) | 14 (8) | |
| ALL cALLa (including Pre-B) | 58 (34) | |
| ALL, B-lineage, NOS | 27 (16) | |
| ALL other | 30 (18) | |
| WBC at diagnosis, ×109/L | 155 | 31 (<1-776) |
| Less than 30 | 77 (50) | |
| 30 to 100 | 40 (26) | |
| 100 to 200 | 25 (16) | |
| More than 200 | 13 (8) | |
| Site of extramedullary disease | 169 | |
| CNS with or without another | 21 (12) | |
| Other* | 10 (6) | |
| No extramedullary disease | 138 (82) | |
| Time from diagnosis to CR1 | 168 | |
| Less than 4 wk | 43 (26) | |
| 4 to 8 wk | 55 (33) | |
| More than 8 wk | 70 (42) | |
| Time from CR1 to transplantation | 169 | |
| Less than 3 mo | 58 (34) | |
| 3 to 6 mo | 70 (41) | |
| More than 6 mo | 41 (24) | |
| Time from diagnosis to transplantation | 169 | |
| Less than 3 mo | 4 (2) | |
| 3 to 6 mo | 67 (40) | |
| More than 6 mo | 98 (58) | |
| Cytogenetics | 169 | |
| t(4;11) with or without others | 27 (16) | |
| Hypodiploid (no t(4;11) or t(8,14)) with or without others | 10 (6) | |
| Five or more abnormalities | 5 (3) | |
| Other | 60 (35) | |
| No abnormalities | 67 (40) | |
| Conditioning regimen | ||
| Cy plus TBI with or without another | 129 (76) | |
| TBI with or without another (no Cy) | 25 (15) | |
| Cy with or without another (no TBI) | 11 (7) | |
| Other | 4 (2) | |
| TBI dose, cGy | 153 | 1200 (200-1500) |
| Less than 1300 | 31 (21) | |
| More than 1300 | 121 (79) | |
| Cyclophosphamide dose, mg/kg | 140 | 117 (8-200) |
| Less than 100 | 32 (23) | |
| 100 to 120 | 55 (39) | |
| More than 120 | 53 (38) | |
| Donor age, y | 163 | 33 (19-56) |
| 20 or younger | 2 (1) | |
| 21 to 30 | 62 (38) | |
| 31 to 40 | 66 (40) | |
| 41 to 50 | 31 (19) | |
| 51 to 60 | 2 (1) | |
| Donor-recipient sex match | 168 | |
| M-M | 75 (44) | |
| M-F | 32 (19) | |
| F-M | 25 (15) | |
| F-F | 36 (21) | |
| Donor-recipient CMV status | 166 | |
| +/+ | 41 (25) | |
| +/− | 28 (17) | |
| −/+ | 44 (27) | |
| −/− | 53 (31) | |
| Donor-recipient HLA match† | 169 | |
| Well matched | 70 (41) | |
| Partially matched | 70 (41) | |
| Mismatched | 29 (18) | |
| Graft type | 169 | |
| Bone marrow | 117 (69) | |
| Peripheral blood | 52 (31) | |
| Year of transplantation | 169 | |
| 1995 to 1996 | 27 (16) | |
| 1997 to 1998 | 23 (14) | |
| 1999 to 2000 | 27 (16) | |
| 2001 to 2002 | 36 (21) | |
| 2003 to 2004 | 56 (33) | |
| GVHD prophylaxis | 169 | |
| (FK506 or CsA) plus MTX with or without another | 130 (77) | |
| T-cell depletion‡ | 16 (9) | |
| Other§ | 23 (14) | |
| Median (range) follow-up of survivors, mo | 54 (3-133) |
TBI indicates total body irradiation; CNS, central nervous system; CY, cyclophosphamide; CsA, cyclosporine; NOS, not otherwise specified; MTX, methotrexate; CR, complete remission; WBC, white blood cell; CMV, cytomegalovirus; GVHD, graft-versus-host disease; FK506, tacrolimus.
Other sites of extramedullary disease were pleura, skeleton (osteolysis), lymph nodes, spleen, liver, skin, lung, and kidney.
Donor-recipient HLA match was defined as follows:
Well matched: matched 8/8 at high-res HLA-A, -B, -C and -DRB1 (n = 41); matched 8/8 at high-res HLA-A, -B and -DRB1 and low-res at HLA-C (n = 5); matched 8/8 at low-res HLA-A, -B and -C and high-res at HLA-DRB1 (n = 21); matched 6/6 at high-res HLA-A, -B and -DRB1 (HLA-C unknown; n = 3).
Partially matched: Single allele MM (7/8) at high-res HLA-A, -B, -C and -DRB1 (n = 9); single antigen MM (7/8) at high-res HLA-A, -B, -C and -DRB1 (n = 15); single MM (7/8) at low-res HLA-A, -B and -C and high-res at HLA-DRB1 (n = 4); matched 8/8 at low-res HLA-A, -B and -C and -DRB1 (n = 4); single allele MM (5/6) at high-res HLA-A, -B and -DRB1 (HLA-C unknown; n = 2); matched 6/6 at low-res HLA-A and -B and high-res at HLA-DRB1 (HLA-C unknown) (n = 36).
Mismatched: 2 or more allele MM (<7/8) at high-res HLA-A, -B, -C and -DRB1 (n = 8); 2 or more MM with 1 antigen MM (<7/8) at high-res HLA-A, -B, -C and -DRB1 (n = 4); 2 or more MM with 2 or more antigen MM (<7/8) at high-res HLA-A, -B, -C and -DRB1 (n = 3); 2 or more MM (<7/8) at high-res HLA-A, -B and -DRB1 and low-res at HLA-C (n = 1); 2 or more MM (<7/8) at low-res HLA-A, -B and -C and high-res at HLA-DRB1 (n = 5); single MM (5/6) at low-res HLA-A and -B and high-res at HLA-DRB1 (HLA-C unknown; n = 6); matched (6/6) at low-res HLA-A and -B and -DRB1 (HLA-C unknown; n = 2).
Sixteen T-depleted grafts at 13 centers used: antibody and complement, 7; immunomagnetics, 4; soybean lectin, 1; elutriation, 1; and missing, 2.
Other GVHD prophylaxis were: FK506 + other (n = 10); CSA + other (n = 13).